Investigational drug · Phase 2
Cadefrecitinib
Also called: GLPG3667
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Dermatomyositis, Systemic Lupus Erythematosus.
Phase 2Last checked: Nov 19, 2026Latest source record: May 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
2
Any phase or sponsor naming "Cadefrecitinib"
First trial start
2023
Feb 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Cadefrecitinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dermatomyositis
- Systemic Lupus Erythematosus
Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Cadefrecitinib" as an intervention, largest first.
- A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus ErythematosusPivotal-lookingCompleted
Lakefront Biotherapeutics NVIndustry
NCT05856448 · 186 participants · Start Jun 28, 2023 · Primary completion Oct 8, 2025
Drug: GLPG3667; Placebo · For: Systemic Lupus Erythematosus
Sites: Tucson, Arizona; La Jolla, California; Rancho Mirage, California · 84 sites in all
Lakefront Biotherapeutics NVIndustry
NCT05695950 · 40 participants · Start Feb 27, 2023 · Primary completion Oct 13, 2025
Drug: GLPG3667; Placebo · For: Dermatomyositis
Sites: Scottsdale, Arizona; Upland, California; Kendall, Florida · 54 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacological Characterization of GLPG3667, a Tyrosine Kinase 2-Selective Inhibitor, for the Treatment of Inflammatory and Autoimmune Diseases.
Cottereaux C, Lepage ML, Parent I, et al. · Inflammation 2026
- Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases.
Mammoliti O, Martina S, Claes P, et al. · J Med Chem 2024
Also in development for Dermatomyositis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.